Drug intelligence / Profile preview

florquinitau F 18

Development stage: Approved
Lead developer: Lantheus
Modality: Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

TAUKLARIFY (florquinitau F 18) is an F18-labeled small molecule radiopharmaceutical developed by Enigma Biomedical USA in collaboration with Lantheus for use in positron emission tomography (PET) imaging. It is specifically indicated for the visualization of tau neurofibrillary tangles (NFTs) in the brains of adult patients with cognitive impairment who are being evaluated for Alzheimer's disease. By binding to aggregated tau protein deposits, a hallmark of Alzheimer's pathology, TAUKLARIFY provides clinicians with a diagnostic tool to assess the presence and density of tau pathology. The agent received FDA approval on August 14, 2026, following Fast Track designation.

Brand names: TAUKLARIFY
Other names: florquinitau F 18 injection

Targets

MAOA (Monoamine oxidase A)Amyloid-beta aggregate (N-terminal epitope)Tau (Microtubule-associated protein tau (aggregated))

Beyond the preview

Go deeper on florquinitau F 18.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on florquinitau F 18.

Explore the full profile